Magnesium Sulphate and Nifedipine in Management of Preterm Premature Rupture of Membranes



Abstract Views
2258

Downloads
705

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Mar 19, 2022
Published Aug 31, 2022
10.24018/ejmed.2022.4.4.1290

Abstract viewed = 2258 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Premature rupture of membranes (PROM) is defined as rupture before delivery that can occur at any gestational age. If it occurs before 37 weeks of gestation, it’s called Preterm Premature Rupture of Membrane (PPROM). PROM is a condition that still occurs in both developed and developing countries and cause a serious threat to the fetal and maternal well-being if not managed properly. Conservative management is chosen in PPROM until the fetus is viable, consist of hospitalization, assessment of sign of infection, well-being of the fetal and maternal. Spesific treatment includes the administration of corticosteroid, antibiotics, and tocolytics. Tocolytic agents that are widely used as first-line agents are magnesium sulphate (MgSO4) and nifedipine, one of the Calcium Channel Blocker (CCB) groups. MgSO4 and nifedipine both have an effect in reducing myometrial contractility. MgSo4 also has a neuroprotective effect in PPROM less than 31 weeks if there is a threat of delivery within 24 hours. Meta-analysis related to the use of these two agents in PPROM is still subject to differing result. Some studies have shown nifedipine is considered to have milder side effect than MgSO4, more easily tolerated by oral administration, and more affordable. However, some studies have shown that the two agents have the same efficacy. Other studies have shown no significant benefit in administering nifedipine to neonates or prolong pregnancy in women with PPROM without contractions.

Keywords: Magnesium sulphate, nifedipine, premature ruptures of membrane, preterm, tocolytic

Downloads

Download data is not yet available.

References

  1. Mamede AC, Carvalho MJ, Abrantes AM, Laranjo M, Maia CJ, Botelho MF. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. 2012; 349(2): 447-458.
    DOI  |   Google Scholar
  2. Pradana TA, Surya HW. Karakteristik Ibu Bersalin Dengan Ketuban Pecah Dini (Aterm & Preterm) di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Juli 2015 – Juni 2016. Jurnal Medika Udayana. 2020; 9(7): 92-7. Indonesian.
     Google Scholar
  3. Byonanuwe S, Nzabandora E, Nyongozi B, et al. Predictors of Premature Rupture of Membranes among Pregnant Women in Rural Uganda: A Cross-Sectional Study at a Tertiary Teaching Hospital. Int J Reprod Med. 2020; 2020: 1862786.
    DOI  |   Google Scholar
  4. Enjamo M, Deribew A, Semagn S, Mareg M. Determinants of Premature Rupture of Membrane (PROM) Among Pregnant Women in Southern Ethiopia: A Case-Control Study. Int J Womens Health. 2022; 14: 455-466.
    DOI  |   Google Scholar
  5. Tchirikov M, Schlabritz-Loutsevitch N, Maher J, Buchmann J, Naberezhnev Y, Winarno AS, et al. Mid-trimester preterm premature rupture of membranes (PPROM): etiology, diagnosis, classification, international recommendations of treatment options and outcome. J Perinat Med. 2018; 46(5): 465-488.
    DOI  |   Google Scholar
  6. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 172: Premature Rupture of Membranes. Obstet Gynecol. 2016; 128(4): e165-e177.
    DOI  |   Google Scholar
  7. Mendez-Figueroa H, Chauhan SP. Tocolytic Therapy in Preterm Premature Rupture of Membranes. Obstet Gynecol Clin North Am. 2020; 47(4): 569-586.
    DOI  |   Google Scholar
  8. Horton AL, Lai Y, Rouse DJ, et al. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes. Am J Perinatol. 2015; 32(4): 387-392.
    DOI  |   Google Scholar
  9. Meller CH, Carducci ME, Ceriani Cernadas JM, Otaño L. Preterm premature rupture of membranes. Arch Argent Pediatr. 2018; 116(4): e575-e581.
    DOI  |   Google Scholar
  10. Lorthe E, Torchin H, Delorme P, Ancel PY, Marchand-Martin L, Foix-l’Helias L, et al. Preterm premature rupture of membranes at 22-25 weeks' gestation: perinatal and 2-year outcomes within a national population-based study (EPIPAGE-2). Am J Obstet Gynecol. 2018; 219(3): 298.e1-298.e14.
    DOI  |   Google Scholar
  11. Lyell DJ, Pullen K, Campbell L, et al. Magnesium sulfate compared with nifedipine for acute tocolysis of preterm labor: a randomized controlled trial. Obstet Gynecol. 2007; 110(1): 61-67.
    DOI  |   Google Scholar
  12. Hanley M, Sayres L, Reiff ES, Wood A, Grotegut CA, Kuller JA. Tocolysis: A Review of the Literature. Obstet Gynecol Surv. 2019; 74(1): 50-55.
    DOI  |   Google Scholar
  13. Berkman ND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, Gavin NI, et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol. 2003; 188(6): 1648-1659.
    DOI  |   Google Scholar
  14. Schleußner E. The prevention, diagnosis and treatment of premature labor. Dtsch Arztebl Int. 2013; 110(13): 227-236.
    DOI  |   Google Scholar
  15. Gáspár R, Hajagos-Tóth J. Calcium channel blockers as tocolytics: principles of their actions, adverse effects and therapeutic combinations. Pharmaceuticals (Basel). 2013; 6(6): 689-699.
    DOI  |   Google Scholar
  16. Nijman TA, van Vliet EO, Naaktgeboren CA, Rengerink KO, de Lange TS, Bax CJ, et al. Nifedipine versus placebo in the treatment of preterm prelabor rupture of membranes: a randomized controlled trial: Assessment of perinatal outcome by use of tocolysis in early labor-APOSTEL IV trial. Eur J Obstet Gynecol Reprod Biol. 2016; 205: 79-84.
    DOI  |   Google Scholar
  17. Lee HH, Yeh CC, Yang ST, Liu CH, Chen YJ, Wang PH. Tocolytic Treatment for the Prevention of Preterm Birth from a Taiwanese Perspective: A Survey of Taiwanese Obstetric Specialists. Int J Environ Res Public Health. 2022; 19(7): 4222.
    DOI  |   Google Scholar
  18. Stelzl P, Kehl S, Oppelt P, Maul H, Enengl S, Kyvernitakis I, et al. Do obstetric units adhere to the evidence-based national guideline? A Germany-wide survey on the current practice of initial tocolysis. Eur J Obstet Gynecol Reprod Biol. 2022; 270: 133-138.
    DOI  |   Google Scholar
  19. McNamara HC, Crowther CA, Brown J. Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour. Cochrane Database Syst Rev. 2015; 2015(12): CD011200.
    DOI  |   Google Scholar
  20. Yasa I, Aman IGM, Satriyasa BK. Tingkat Keberhasilan Nifedipin Sebagai Tokolitik Pada Pasien Partus Prematurus Imminens di Rumah Sakit Umum Pusat Sanglah Denpasar. Jurnal Medika Udayana. 2019; 8(5): 1-11.
     Google Scholar
  21. Gathwala G. Neuronal protection with magnesium. Indian J Pediatr. 2001; 68(5): 417-419.
    DOI  |   Google Scholar
  22. Bachnas MA, Mose JC, Effendi JS, Andonotopo W. Influence of antenatal magnesium sulfate application on cord blood levels of brain-derived neurotrophic factor in premature infants. J Perinat Med. 2014; 42(1): 129-134.
    DOI  |   Google Scholar


Most read articles by the same author(s)

1 2 3 4 > >>